Buy Darunavir (Prezista) tablets online

Buy Darunavir (Prezista) online

How and where to order Prezista (Darunavir Ethanolate) 600 mg, 800 mg tablets or capsules online:

Shop: PHARM X SELLER
- 10% discount coupon 918cc60b466a42ba

Sellers: DARUNAVIR STORES

Prices: from $3.32 per pill

Forms: 600 mg, 800 mg tablets

Quantity: 30-600 pills

Type: Daruvir brand, Prezista generic

Payment: Visa, Mastercard, AmEx, Cryptocurrency

Delivery: Regular and express mail service

Shipping: Worldwide, including USA, UK, Europe, Canada, Australia

Indications and usage:

Prezista (Darunavir Ethanolate) is a human immunodeficiency virus (HIV-1) protease inhibitor indicated for the treatment of HIV-1 infection in adult and pediatric patients 3 years of age and older. This drug must be co-administered with ritonavir and other antiretroviral agents.

Contraindications:

Co-administration of Prezista/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (narrow therapeutic index).

Dosage forms and strengths:

Prezista (Darunavir Ethanolate) oral suspension: 100 mg / ml.

Prezista (Darunavir Ethanolate) tablets 75 mg, 150 mg, 600 mg, 800 mg.

Dosage and administration:

Testing:

- In treatment-experienced patients, treatment history genotypic and/or phenotypic testing is recommended prior to initiation of therapy with Prezista/ritonavir to assess drug susceptibility of the HIV-1 virus.
- Monitor serum liver chemistry tests before and during therapy with this medication.

Treatment-naive adult patients and treatment-experienced adult patients with no darunavir resistance associated substitutions: 800 mg (one 800 mg tablet) taken with ritonavir 100 mg once daily and with food.

Treatment-experienced adult patients with at least one darunavir resistance associated substitution: 600 mg (one 600 mg tablet) taken with ritonavir 100 mg twice daily and with food.

Pregnant patients: 600 mg (one 600 mg tablet) taken with ritonavir 100 mg twice daily and with food.

Pediatric patients (3 to less than 18 years of age and weighing at least 10 kg): dosage of darunavir and ritonavir is based on body weight and should not exceed the adult dose. Prezista should be taken with ritonavir and with food.

This medicine is not recommended for use in patients with severe hepatic impairment.

Warnings and precautions:

Drug-induced hepatitis (e.g., acute hepatitis, cytolytic hepatitis) has been reported with Prezista/ritonavir. Monitor liver function before and during therapy, especially in patients with underlying chronic hepatitis, cirrhosis, or in patients who have pre-treatment elevations of transaminases. Post-marketing cases of liver injury, including some fatalities, have been reported.

Skin reactions ranging from mild to severe, including Stevens-Johnson Syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms and acute generalized exanthematous pustulosis, have been reported. Discontinue treatment if severe reaction develops.

Use with caution in patients with a known sulfonamide allergy.

Patients may develop new onset diabetes mellitus or hyperglycemia. Initiation or dose adjustments of insulin or oral hypoglycemic agents may be required.

Patients may develop redistribution/accumulation of body fat or immune reconstitution syndrome.

Patients with hemophilia may develop increased bleeding events.

Prezista/ritonavir is not recommended in pediatric patients below 3 years of age in view of toxicity and mortality observed in juvenile rats dosed with darunavir up to days 23 to 26 of age.

Overdosage:

Human experience of acute overdose with Prezista/ritonavir is limited. No specific antidote is available for overdose with darunavir ethanolate. Treatment of overdose with this drug consists of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. Since Prezista (Darunavir) is highly protein bound, dialysis is unlikely to be beneficial in significant removal of the active substance.

Side effects, adverse reactions:

The most common clinical adverse drug reactions to darunavir/ritonavir (incidence greater than or equal to 5%) of at least moderate intensity (greater than or equal to Grade 2) were diarrhea, nausea, rash, headache, abdominal pain and vomiting.

To report suspected side effects of Prezista (Darunavir Ethanolate) tablets and oral suspension contact Janssen pharmaceutical company or your local FDA.

Drug interactions:

Co-administration of Prezista/ritonavir with other drugs can alter the concentrations of other drugs and other drugs may alter the concentrations of darunavir. The potential drug-drug interactions must be considered prior to and during therapy.

Usage in specific populations:

Pregnancy

Total darunavir exposures were generally lower during pregnancy compared to postpartum period. The reduction in darunavir exposures during pregnancy were greater for once daily dosing compared to the twice daily dosing regimen.

Lactation

Women infected with HIV should be instructed not to breastfeed due to the potential for HIV transmission.

Pediatrics

Not recommended for patients less than 3 years of age.

Patient counseling information:

Advise the patient to read the FDA-approved patient labeling (patient information and instruction for use).

Instructions for use

Advise patients to take Prezista (Darunavir Ethanolate) and ritonavir with food every day on a regular dosing schedule, as missed doses can result in development of resistance. This mediction must always be used with ritonavir in combination with other antiretroviral drugs. Advise patients not to alter the dose of either Prezista or ritonavir, discontinue ritonavir, or discontinue therapy with this medicine without consulting their physician.

Hepatotoxicity

Inform patients that drug-induced hepatitis (e.g., acute hepatitis, cytolytic hepatitis) has been reported with Prezista co-administered with 100 mg of ritonavir. Advise patients about the signs and symptoms of liver problems.

Severe skin reactions

Inform patients that skin reactions ranging from mild to severe, including Stevens-Johnson Syndrome, drug rash with eosinophilia and systemic symptoms, and toxic epidermal necrolysis, have been reported with this drug co-administered with 100 mg of ritonavir. Advise patients to discontinue Prezista/ritonavir immediately if signs or symptoms of severe skin reactions develop. These can include but are not limited to severe rash or rash accompanied with fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, hepatitis and/or eosinophilia.

Drug interactions

Prezista/ritonavir may interact with many drugs; therefore, advise patients to report to their healthcare provider the use of any other prescription or nonprescription medication or herbal products, including St. John's wort.

Contraception

Instruct patients receiving combined hormonal contraception or the progestin only pill to use an effective alternative (non-hormonal) contraceptive method or add a barrier method during therapy with darunavir/ritonavir because hormonal levels may decrease.

Fat redistribution

Inform patients that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy, including Prezista/ritonavir, and that the cause and long-term health effects of these conditions are not known at this time.

Immune reconstitution syndrome

Advise patients to inform their healthcare provider immediately of any symptoms of infection, as in some patients with advanced HIV infection (AIDS), signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started.

Pregnancy registry

Inform patients that there is an antiretroviral pregnancy registry to monitor fetal outcomes of pregnant women exposed to Prezista.

Lactation

Instruct women with HIV-1 infection not to breastfeed because HIV-1 can be passed to the baby in breast milk.

Where to buy darunavir online:

To purchase Prezista (Darunavir Ethanolate) 600 mg, 800 mg tablets from reliable online pharmacies and drugstores at low prices please use resources described above on this webpage.

Here is a list of popular medications containing darunavir ethanolate as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:

Trade name of the drug	Pharmaceutical forms and doses	Companies
Daruvir	Tablets, Film-Coated; Oral; 300 mg, 600 mg, 800 mg	Cipla
Prezista	Suspension; Oral; 100 mg / ml Tablets, Film-Coated; Oral; 75 mg, 150 mg, 600 mg, 800 mg	Janssen
Virem	Tablets, Film-Coated; Oral; 300 mg, 600 mg	Emcure Pharmaceuticals